Axsome Therapeutics Inc . (NASDAQ:AXSM) stock soared to a 52-week high, reaching a price level of $105.18. The biopharmaceutical company, with a market capitalization of $5 billion, has demonstrated ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on AXSM stock, giving a Buy rating on January 24.Invest with ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at ...

Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and set a price target ...

AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report issued ...

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of ...

H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...

Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in ...

About Axsome Therapeutics, Inc. Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by ...

About Axsome Therapeutics, Inc. Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific ...